Femme et Homme
- | Pays :
- Ukraine
- Italy
- United States
- | Organes : -
- | Spécialités : -
Extrait
The primary efficacy objective of this study is to evaluate the difference in coefficient of fat absorption (CFA) of participants treated with high dose EUR-1008 (APT-1008) versus low dose of EUR-1008 (APT-1008) in the treatment of signs and symptoms of malabsorption in participants with EPI associated with CP. This study is sponsored by Aptalis Pharma (formerly Eurand).
Critère d'inclusion
- Chronic pancreatitis ,Exocrine Pancreatic Insufficiency